A booster dose of the Pfizer-BioNTech COVID-19 vaccine sparked a strong immune response in children ages 5 to 11, the companies jointly announced on Thursday.
Pfizer and its partner company BioNTech will request authorization from the Food and Drug Administration to give third doses to children approximately six months after the second dose. A phase 2/3 clinical trial found that the booster raised antibodies against the omicron variant thirty-sixfold compared to levels seen after two shots.
“These data demonstrate an increase in SARS-CoV-2 Omicron variant and wild-type strain neutralizing titers following a booster dose of the Pfizer-BioNTech COVID-19 vaccine compared to two doses,” the companies said. “These data reinforce the potential function of a third dose of the vaccine in maintaining high levels of protection against the virus in this age group.
They conducted trials of a 3 microgram dose of the COVID-19 vaccine for children under 5 but announced in December it had failed to produce a strong immune response and that adding a third dose would be necessary. The companies submitted the application for authorization of shots for this age group despite the lack of clinical trial data to back them up.Still, administering the vaccines to young children has been controversial.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Pfizer to seek COVID-19 booster for healthy 5- to 11-year-oldsPfizer said Thursday it wants to expand its COVID-19 booster shots to healthy elementary-age kids.
Weiterlesen »
Pfizer Says Covid-19 Booster in Children Ages 5 to 11 Sparked Immune Response Against OmicronA booster shot of the Pfizer-BioNTech Covid vaccine in children ages 5 to 11 significantly increased antibody levels against the Omicron variant as well as against the initial strain it was designed to fight, a late-stage study found.
Weiterlesen »
COVID-19 booster: Pfizer to seek extra shot for healthy kids 5 to 11Pfizer said new data shows its kid-sized COVID-19 booster could help healthy elementary-aged children rev up virus-fighting antibodies and plans to seek authorization soon.
Weiterlesen »
Pfizer may have COVID-19 booster that addresses omicron, other variants by fallBy this fall, Pfizer and its partner BioNTech could potentially have a COVID-19 booster that specifically addresses the omicron variant as well as its subvariants and other known strains of the virus, CEO Albert Bourla said during a panel.
Weiterlesen »
Pfizer to seek COVID booster for healthy 5- to 11-year-oldsNEW: Pfizer says it wants to expand its COVID-19 booster shots to healthy elementary-age kids.
Weiterlesen »